Paratek Pharmaceuticals (NASDAQ: PRTK) rose 7.1% to $17.60. Paratek reported that Omadacycline has met all primary and secondary efficacy outcomes designated by the FDA and EMA in a Phase 3 study in acute bacterial skin infections. Share volume was 872,000, compared to an all-day average of 77,000
